Yin S[au] - Search Results

Year	Number of Results
1956	2
1967	1
1968	2
1971	2
1976	2
1977	1
1979	1
1980	3
1981	3
1982	5
1983	4
1984	6
1985	3
1986	6
1987	6
1988	7
1989	16
1990	13
1991	18
1992	10
1993	20
1994	24
1995	14
1996	29
1997	23
1998	18
1999	24
2000	21
2001	29
2002	31
2003	47
2004	50
2005	73
2006	77
2007	94
2008	125
2009	141
2010	130
2011	158
2012	161
2013	208
2014	215
2015	309
2016	325
2017	352
2018	418
2019	506
2020	570
2021	629
2022	489

1

Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.

Li Y, Xia Y, Yin S, Wan F, Hu J, Kou L, Sun Y, Wu J, Zhou Q, Huang J, Xiong N, Wang T. Li Y, et al. Among authors: yin s. Front Immunol. 2021 Oct 8;12:719807. doi: 10.3389/fimmu.2021.719807. eCollection 2021. Front Immunol. 2021. PMID: 34691027 Free PMC article. Review.

2

N⁶ -Methyladenosine and Rheumatoid Arthritis: A Comprehensive Review.

Wu S, Li XF, Wu YY, Yin SQ, Huang C, Li J. Wu S, et al. Among authors: yin sq. Front Immunol. 2021 Sep 24;12:731842. doi: 10.3389/fimmu.2021.731842. eCollection 2021. Front Immunol. 2021. PMID: 34630412 Free PMC article. Review.

3

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.

Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R, Szychowski J, Veloso A, Alam H, Baruah PS, Fortin AB, Bowlan J, Chaudhary N, Desjardins J, Dietrich E, Fournier S, Fugère-Desjardins C, Goullet de Rugy T, Leclaire ME, Liu B, Bhaskaran V, Mamane Y, Melo H, Nicolas O, Singhania A, Szilard RK, Tkáč J, Yin SY, Morris SJ, Zinda M, Marshall CG, Durocher D. Gallo D, et al. Among authors: yin sy. Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20. Nature. 2022. PMID: 35444283 Free PMC article.

4

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.

Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: yin s. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. J Clin Oncol. 2022. PMID: 34914545 Clinical Trial.

5

Two-Dimensional Heterojunction Electrocatalyst: Au-Bi₂Te₃ Nanosheets for Electrochemical Ammonia Synthesis.

Liu M, Yin S, Ren T, Xu Y, Wang Z, Li X, Wang L, Wang H. Liu M, et al. Among authors: yin s. ACS Appl Mater Interfaces. 2021 Oct 13;13(40):47458-47464. doi: 10.1021/acsami.1c11246. Epub 2021 Oct 4. ACS Appl Mater Interfaces. 2021. PMID: 34605239

6

Blocking CD47 promotes antitumour immunity through CD103⁺ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.

Wang S, Wu Q, Chen T, Su R, Pan C, Qian J, Huang H, Yin S, Xie H, Zhou L, Zheng S. Wang S, et al. Among authors: yin s. J Hepatol. 2022 Aug;77(2):467-478. doi: 10.1016/j.jhep.2022.03.011. Epub 2022 Apr 1. J Hepatol. 2022. PMID: 35367532

7

In vitro studies of maleidride-forming enzymes.

Yin S, Friedrich S, Hrupins V, Cox RJ. Yin S, et al. RSC Adv. 2021 Apr 21;11(25):14922-14931. doi: 10.1039/d1ra02118d. eCollection 2021 Apr 21. RSC Adv. 2021. PMID: 35424071 Free PMC article.

8

Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine.

Chen Y, Yin S, Tong X, Tao Y, Ni J, Pan J, Li M, Wan Y, Mao M, Xiong Y, Yan X, Yang Y, Huang R, Wu C, Shen H. Chen Y, et al. Among authors: yin s. Clin Microbiol Infect. 2022 Mar;28(3):410-418. doi: 10.1016/j.cmi.2021.10.006. Epub 2021 Oct 26. Clin Microbiol Infect. 2022. PMID: 34715346 Free PMC article.

9

Thresholded single-photon underwater imaging and detection.

Li ZM, Zhou H, Li ZY, Yan ZQ, Hu CQ, Gao J, Wu SB, Yin SY, Jin XM. Li ZM, et al. Among authors: yin sy. Opt Express. 2021 Aug 30;29(18):28124-28133. doi: 10.1364/OE.436013. Opt Express. 2021. PMID: 34614951 Free article.

10

Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment.

Yin S, Jin W, Qiu Y, Fu L, Wang T, Yu H. Yin S, et al. J Hematol Oncol. 2022 Mar 21;15(1):32. doi: 10.1186/s13045-022-01248-w. J Hematol Oncol. 2022. PMID: 35313929 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results